Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide and recently emerged as the most rapidly increasing indication for liver transplant. Although obesity is a risk factor for NAFLD, overlap between these two entities is incompletely understood. We highlight recent insights into the pathogenesis of human NAFLD in relation to obesity and discuss advances in the diagnosis and treatment of NAFLD.
Copyright © 2016, American Association for the Advancement of Science.
MeSH terms
-
Adenosine Triphosphate / metabolism
-
Adipocytes / cytology
-
Animals
-
Biomarkers / metabolism
-
Body Mass Index
-
Diet
-
Disease Progression
-
Fibrosis / metabolism
-
Hepatocytes / cytology
-
Humans
-
Inflammation
-
Insulin Resistance
-
Liver / metabolism
-
Non-alcoholic Fatty Liver Disease / complications*
-
Non-alcoholic Fatty Liver Disease / diagnosis
-
Non-alcoholic Fatty Liver Disease / metabolism
-
Non-alcoholic Fatty Liver Disease / therapy
-
Obesity / complications*
-
Obesity / metabolism
-
Oxidative Stress
-
Reactive Oxygen Species / metabolism
-
Risk Factors
-
Weight Loss
Substances
-
Biomarkers
-
Reactive Oxygen Species
-
Adenosine Triphosphate